Brokerages Set IQVIA Holdings Inc. (NYSE:IQV) PT at $241.88

IQVIA Holdings Inc. (NYSE:IQV) has earned a consensus rating of “Moderate Buy” from the seventeen ratings firms that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $241.8824.

IQV has been the topic of a number of recent analyst reports. HSBC reaffirmed a “buy” rating and issued a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. Barclays restated an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. William Blair raised shares of IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. TD Cowen boosted their target price on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Finally, Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday.

IQVIA Stock Down 0.7%

NYSE IQV opened at $260.48 on Monday. The business has a fifty day moving average price of $222.14 and a 200 day moving average price of $189.62. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The company has a market cap of $42.88 billion, a P/E ratio of 32.32, a P/E/G ratio of 2.24 and a beta of 1.18. IQVIA has a one year low of $154.50 and a one year high of $265.25.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same period in the prior year, the business earned $2.81 EPS. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts anticipate that IQVIA will post 11.57 EPS for the current fiscal year.

IQVIA declared that its board has approved a stock repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 12,913 shares of company stock worth $3,098,793 in the last 90 days. Company insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On IQVIA

Large investors have recently made changes to their positions in the stock. Apella Capital LLC increased its stake in IQVIA by 5.1% in the 1st quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock valued at $211,000 after purchasing an additional 58 shares in the last quarter. Quadrant Capital Group LLC boosted its position in IQVIA by 1.3% during the fourth quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock worth $1,080,000 after purchasing an additional 60 shares in the last quarter. Private Advisor Group LLC grew its holdings in IQVIA by 1.0% in the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after purchasing an additional 63 shares during the last quarter. Breakwater Capital Group increased its position in shares of IQVIA by 3.2% in the second quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after buying an additional 64 shares in the last quarter. Finally, Keybank National Association OH raised its stake in shares of IQVIA by 0.7% during the 4th quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock worth $2,052,000 after buying an additional 67 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.